The PARP7 gene signature developed in this study correlates with poor prognosis and immune suppression in TNBC patients, and may serve as a predictive biomarker for future clinical trials evaluating PARP7i with concurrent radioimmunotherapy in ICI-resistant cancers. This evidence concerns the gene TIPARP and cancer.